BCR-ABL1/ABL1IS
Chronic Myeloid Leukemia
doubling-time
halving-time
tyrosine kinase inhibitors
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
04
2019
accepted:
29
07
2019
entrez:
29
8
2019
pubmed:
29
8
2019
medline:
29
8
2019
Statut:
epublish
Résumé
In Chronic Myeloid Leukemia (CML), successful treatment requires accurate molecular monitoring to evaluate disease response and provide timely interventions for patients failing to achieve the desired outcomes. We wanted to determine whether measuring
Identifiants
pubmed: 31456947
doi: 10.3389/fonc.2019.00764
pmc: PMC6700306
doi:
Types de publication
Journal Article
Langues
eng
Pagination
764Références
Nature. 2005 Jun 30;435(7046):1267-70
pubmed: 15988530
Blood. 2006 Jul 1;108(1):28-37
pubmed: 16522812
Leukemia. 2008 Jan;22(1):96-102
pubmed: 17943168
Blood. 2008 Oct 15;112(8):3330-8
pubmed: 18684859
Int J Cancer. 2009 Jun 1;124(11):2539-48
pubmed: 19173293
Acta Oncol. 2010 May;49(4):506-8
pubmed: 20331405
PLoS One. 2011 Feb 11;6(2):e17020
pubmed: 21347248
Acta Haematol. 2011;126(4):205-10
pubmed: 21934293
J Clin Oncol. 2012 Jan 20;30(3):232-8
pubmed: 22067393
Blood. 2012 May 3;119(18):4264-71
pubmed: 22431575
Leukemia. 2012 Oct;26(10):2172-5
pubmed: 22504141
Blood. 2013 Jan 10;121(2):378-84
pubmed: 23175686
Mol Cancer Ther. 2013 Jun;12(6):1085-98
pubmed: 23536723
BMC Cancer. 2013 Apr 02;13:173
pubmed: 23547655
Blood. 2013 Jul 25;122(4):515-22
pubmed: 23704092
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
Oncology (Williston Park). 2013 Sep;27(9):899-906
pubmed: 24282988
J Clin Oncol. 2014 Feb 10;32(5):415-23
pubmed: 24297946
Carcinogenesis. 2014 May;35(5):1132-43
pubmed: 24445143
Oncology (Williston Park). 2013 Dec;27(12):1263-9, 1274-9
pubmed: 24624545
Leukemia. 2014 Oct;28(10):1988-92
pubmed: 24798484
Blood. 2014 Jul 24;124(4):511-8
pubmed: 24859364
Cancer Cell. 2014 Sep 8;26(3):428-442
pubmed: 25132497
Curr Cancer Drug Targets. 2016;16(7):594-605
pubmed: 26728039
Leukemia. 2016 May;30(5):1044-54
pubmed: 26837842
Expert Rev Anticancer Ther. 2016;16(3):273-8
pubmed: 26852913
Blood. 2016 Jul 7;128(1):17-23
pubmed: 27013442
J Clin Oncol. 2016 Jul 10;34(20):2333-40
pubmed: 27217448
Mol Cell Endocrinol. 2017 Dec 5;457:73-80
pubmed: 27794445
J Clin Oncol. 2017 Jan 20;35(3):298-305
pubmed: 28095277
Cancer Sci. 2017 Nov;108(11):2204-2212
pubmed: 28801986
Clin Cancer Res. 2017 Dec 1;23(23):7189-7198
pubmed: 28928163
Pathology. 2018 Jan;50(1):74-87
pubmed: 29167021
Mol Cancer. 2018 Feb 19;17(1):56
pubmed: 29455672
Lancet Oncol. 2018 Jun;19(6):747-757
pubmed: 29735299
Haematologica. 2019 Aug;104(8):1589-1596
pubmed: 30819917
Int J Mol Sci. 2019 May 06;20(9):null
pubmed: 31064152